Cantor Fitzgerald Reiterates Overweight Rating on X4 Pharmaceuticals (XFOR)

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $3.00 price target on X4 Pharmaceuticals (NASDAQ: XFOR).

The analyst commented, “While many investors are bullish on the opportunity in CN, the financing overhang on the stock and lack of near-term catalysts have created pressure on shares. Given the XOLREMDI launch has been at a slow start, we think most investor focus will remain on CN. XOLREMDI will remain a show-me commercial story, but the company has been strategic to out-license in other territories, supporting the balance sheet.”

For an analyst ratings summary and ratings history on X4 Pharmaceuticals click here. For more ratings news on X4 Pharmaceuticals click here.

Shares of X4 Pharmaceuticals closed at $0.26 yesterday.

You May Also Be Interested In

• Hyperion DeFi, Inc. (HYPD) PT Raised to $7.10 at Cantor Fitzgerald
• Benchmark Reiterates Buy Rating on NANO Nuclear Energy (NNE)
• Jumia Technologies (JMIA) PT Lowered to $11 at Cantor Fitzgerald